195733-43-8 Usage
Uses
Used in Pharmaceutical Industry:
(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride is used as a potential therapeutic agent for various medical conditions. Its unique structure and functional groups allow it to interact with specific biological targets, such as receptors or enzymes, which may lead to the development of new drugs for treating diseases.
Used in Chemical Research:
In the field of chemical research, (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride can be used as a starting material or a building block for the synthesis of more complex molecules with specific properties and applications. Its chiral centers and diverse functional groups make it an interesting candidate for further exploration in organic chemistry and drug discovery.
Used in Drug Delivery Systems:
Similar to gallotannin, (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride can be incorporated into drug delivery systems to improve its bioavailability and therapeutic efficacy. By using various carriers such as organic or metallic nanoparticles, the compound can be delivered more effectively to target cells or tissues, enhancing its potential as a pharmaceutical agent.
Check Digit Verification of cas no
The CAS Registry Mumber 195733-43-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,5,7,3 and 3 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 195733-43:
(8*1)+(7*9)+(6*5)+(5*7)+(4*3)+(3*3)+(2*4)+(1*3)=168
168 % 10 = 8
So 195733-43-8 is a valid CAS Registry Number.
InChI:InChI=1/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1
195733-43-8Relevant academic research and scientific papers
Wittenberger, Steven J.,McLaughlin, Maureen A.
, p. 7175 - 7178 (1999)
An enantioselective synthesis of ABT-627 is described. The key transformation is a diastereoselective 6-endo-trig cyclization to produce a 3,4,5-trisubstituted-1,2-oxazine which is ring contracted to the 2,3,4-tri-substituted-pyrrolidine core of ABT-627.
ATRASENTAN HYDROCHLORIDE CRYSTALLINE FORM 2
-
Page/Page column 9, (2008/12/05)
Atrasentan Hydrochloride Crystalline Form 2, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
CRYSTALLINE FORM 1 OF ATRASENTAN HXDROCHLORIDE
-
Page/Page column 26, (2008/06/13)
Atrasentan Hydrochloride Crystalline Form 1, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Crystalline form of a drug
-
Page/Page column 10, (2010/10/20)
Atrasentan Hydrochloride Crystalline Form 2, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
CRYSTALLINE FORM OF ATRASENTAN HYDROCHLORIDE
-
Page/Page column 15, (2010/10/20)
Substantially amorphous atrasentan hydrochloride, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Endothelin antagonists
-
, (2008/06/13)
A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
